At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MTVA MetaVia Inc
Post-Mkt 04-24 17:36:48 EDT
1.56
+0.04
+2.63%
盘后1.57
+0.01+0.64%
17:33 EDT
High1.62Low1.51Vol147.44K
Open1.55D1 Closing1.52Amplitude7.30%
Mkt Cap7.94MTradable Cap5.17MTotal Shares5.09M
T/O231.61KT/O Rate4.45%Tradable Shares3.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MetaVia announces annual shareholder meeting webcast
Reuters  ·  04-16
MetaVia announces annual shareholder meeting webcast
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
TIPRANKS  ·  04-10
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726
Reuters  ·  04-10
MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726
Metavia Inc - Data From Phase 1 Part 3 Trial Expected in Q4 2026
THOMSON REUTERS  ·  04-10
Metavia Inc - Data From Phase 1 Part 3 Trial Expected in Q4 2026
Metavia Doses the First Patient in Higher-Dose Phase 1 Study of Da-1726, Its Glp-1 and Glucagon Dual Agonist for the Treatment of Obesity
THOMSON REUTERS  ·  04-10
Metavia Doses the First Patient in Higher-Dose Phase 1 Study of Da-1726, Its Glp-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
TIPRANKS  ·  04-02
MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating
MetaVia Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-28
MetaVia Is Maintained at Buy by HC Wainwright & Co.
MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025
Reuters  ·  03-27
MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025
MetaVia Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-27
MetaVia Inc reports results for the quarter ended December 31 - Earnings Summary
BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate Update
Reuters  ·  03-26
BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate Update
MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate
Benzinga  ·  03-26
MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate
MetaVia FY2025 net loss narrows 53% to $13 million; R&D expenses drop 68% to $7 million
Reuters  ·  03-26
MetaVia FY2025 net loss narrows 53% to $13 million; R&D expenses drop 68% to $7 million
Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
Dow Jones  ·  03-26
Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
ADVISORY-Alert wrongly tagged to Metavia Inc withdrawn
Reuters  ·  03-26
ADVISORY-Alert wrongly tagged to Metavia Inc withdrawn
MetaVia Inc expected to post a loss of $1.24 a share - Earnings Preview
Reuters  ·  03-20
MetaVia Inc expected to post a loss of $1.24 a share - Earnings Preview
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
Reuters  ·  03-19
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Reuters  ·  03-18
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control
Reuters  ·  03-18
BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control
MetaVia wins IRB approval for Phase 1 Part 3 trial of DA-1726 in obesity
Reuters  ·  03-18
MetaVia wins IRB approval for Phase 1 Part 3 trial of DA-1726 in obesity
Metavia Advances Glp-1-Based Obesity Program With Irb Approval for Higher-Dose Phase 1 Studies of Da-1726, a Glp-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
THOMSON REUTERS  ·  03-18
Metavia Advances Glp-1-Based Obesity Program With Irb Approval for Higher-Dose Phase 1 Studies of Da-1726, a Glp-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Introduction

Company Name.
MetaVia Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Issue price:
--